Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 10Recruiting 3Unknown 2Terminated 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 43Stomach Neoplasms 42Rectal Neoplasms 28Pancreatic Neoplasms 16Lymphoma, Large B-Cell, Diffuse 13Colonic Neoplasms 13Cholangiocarcinoma 11Neoplasm Metastasis 10Adenocarcinoma 10Neoplasms 9Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 7Biliary Tract Neoplasms 7Locally Advanced Rectal Cancer 6Gastrointestinal Neoplasms 6Gallbladder Neoplasms 6Esophageal Neoplasms 6Adenocarcinoma Of Esophagus 6Recurrence 5Peritoneal Neoplasms 5Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 3Carcinoma 3Bile Duct Neoplasms 3Appendiceal Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Pathologic Complete Response 2Melanoma 2Lymphoma, Non-Hodgkin 2

Interventions

Gemcitabine 5Cisplatin 5Oxaliplatin 3durvalumab 2zimberelimab 1trametinib 1tivozanib 1tislelizumab 1quemliclustat 1pertuzumab 1pembrolizumab 1irinotecan sucrosofate 1anlotinib 1Yttrium-90 1Tissue Adhesives 1Stents 1Ritonavir 1Radiosurgery 1Radiofrequency Ablation 1Positron Emission Tomography Computed Tomography 1Photosensitizing Agents 1Photochemotherapy 1Pancreaticojejunostomy 1Liver Transplantation 1Leucovorin 1Itraconazole 1Fluorouracil 1Floxuridine 1FAPI-46 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Bile Duct Neoplasms × Oxaliplatin × Clear all
NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT05849480 2026-03-24

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms

NCT07025174 2025-06-17

SAIB

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡